🇺🇸 AMGN — Amgen Inc.

Healthcare Compra
← Volver

Precio actual

393,17 USD

Máx. histórico

447,03

14 días

Split 2:1 del 22/11/1999

Caída desde máximo

-12,05%

Rango 52 semanas

269,77 – 447,03

Variación hoy

-10,08%

Cierre anterior

437,23

Rango de hoy

391,17 – 410,03

Volumen hoy

6.589.429

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
24,44 (puede no estar actualizado)
Dividend yield
2,31% (puede no estar actualizado)
Precio objetivo analistas
389,69 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 6 horas
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,53%
Fecha de pago Importe por participación
14/02/2019 1,4500 USD
15/11/2018 1,3200 USD
16/08/2018 1,3200 USD
16/05/2018 1,3200 USD
14/02/2018 1,3200 USD
16/11/2017 1,1500 USD
15/08/2017 1,1500 USD
15/05/2017 1,1500 USD
13/02/2017 1,1500 USD
14/11/2016 1,0000 USD
15/08/2016 1,0000 USD
13/05/2016 1,0000 USD
11/02/2016 1,0000 USD
12/11/2015 0,7900 USD
13/08/2015 0,7900 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
24/02/2004 63,00 64,40 63,00 63,27 +0,24% 2,22% 6.447.000
23/02/2004 63,57 63,73 63,02 63,12 -0,71% 1,12% 5.835.700
20/02/2004 63,92 64,27 63,02 63,57 +0,47% 1,96% 7.153.900
19/02/2004 64,58 64,89 63,26 63,27 -1,26% 2,52% 7.129.400
18/02/2004 64,54 65,11 64,08 64,08 -0,73% 1,60% 6.941.100
17/02/2004 65,04 65,32 64,32 64,55 -0,19% 1,54% 5.595.200
13/02/2004 65,11 65,76 64,66 64,67 -1,04% 1,69% 5.707.100
12/02/2004 65,23 66,15 65,05 65,35 -0,74% 1,69% 6.961.900
11/02/2004 64,88 66,08 64,61 65,84 +1,34% 2,27% 7.171.800
10/02/2004 64,13 65,05 63,71 64,97 +1,17% 2,09% 7.145.500
09/02/2004 65,25 65,30 64,15 64,22 -0,99% 1,76% 6.173.400
06/02/2004 64,63 65,56 64,60 64,86 +0,48% 1,49% 6.605.500
05/02/2004 65,75 65,85 64,33 64,55 -1,24% 2,31% 8.331.500
04/02/2004 66,03 66,50 65,25 65,36 -1,31% 1,89% 8.205.000
03/02/2004 66,25 66,70 65,77 66,23 +0,15% 1,40% 7.330.200
02/02/2004 64,65 66,88 64,51 66,13 +2,27% 3,67% 11.028.000
30/01/2004 64,93 65,11 64,49 64,66 -0,51% 0,95% 6.730.800
29/01/2004 64,37 65,30 64,27 64,99 +1,07% 1,60% 8.966.700
28/01/2004 64,81 65,50 64,08 64,30 -0,31% 2,19% 11.384.600
27/01/2004 64,85 65,20 64,44 64,50 -1,27% 1,17% 7.469.500
26/01/2004 63,62 65,73 63,49 65,33 +2,19% 3,52% 11.058.900
23/01/2004 62,03 64,30 61,65 63,93 +4,00% 4,27% 15.874.400
22/01/2004 62,99 63,47 61,10 61,47 -2,13% 3,76% 17.198.800
21/01/2004 62,87 63,49 62,57 62,81 -0,22% 1,46% 10.976.900
20/01/2004 64,00 64,08 62,76 62,95 -0,87% 2,06% 9.380.100
16/01/2004 63,58 63,92 63,34 63,50 +0,55% 0,91% 11.376.900
15/01/2004 64,24 64,49 63,06 63,15 -1,41% 2,23% 11.031.400
14/01/2004 63,80 64,40 63,60 64,05 +0,47% 1,25% 10.241.400
13/01/2004 63,14 63,80 62,95 63,75 +1,14% 1,35% 8.559.500
12/01/2004 63,26 63,40 62,04 63,03 +0,05% 2,15% 7.963.900